#bladdercancer — Public Fediverse posts

Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study

Combat Medical (Combat), a medical device company optimizing the delivery and efficacy of cancer therapeutics, today announced new…
#NewsBeep #News #Health #AU #Australia #Bladder #BladderCancer #Cancer #Efficacy #Hospital #Muscle #Surgery #Therapeutics
https://www.newsbeep.com/au/958190/

https://www.europesays.com/ie/773522/ Combat Medical reports 68% high-grade recurrence-free survival at 12 months in BCG-unresponsive non-muscle invasive bladder cancer study #Bladder #BladderCancer #cancer #Efficacy #Éire #Health #hospital #IE #Ireland #Muscle #Surgery #Therapeutics